Repatha (evolucumab) is now avaliable at a discounted cash price through Amgen's new direct-to-patient program, AmgenNow, and through GoodRx, according to today’s news release .

Repatha is now available for a cash price of $239 a month, which is approximately 60% lower than the current list price in the United States, which is $572.70 . This offer is available to all patients, including those who are on Medicare, Medicaid or are uninsured. It is available at the more than 70,000 participating GoodRx pharmacies nationwide. Amgen also plans to make Repatha available through the TrumpRx website.

“GoodRx is serving as the digital storefront to make Repatha more accessible for patients, leveraging our extensive retail pharmacy network to ensure it’s available where they already fill their

See Full Page